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2Musculoskeletal

The adenosine diphosphate (ADP) receptor P2RY12 (purinergic receptor P2Y, G protein coupled, 12) plays a
critical role in platelet aggregation, and P2RY12 inhibitors are used clinically to prevent cardiac and cerebral
thrombotic events. Extracellular ADP has also been shown to increase osteoclast (OC) activity, but the role of
P2RY12 in OC biology is unknown. Here, we examined the role of mouse P2RY12 in OC function. Mice lacking
P2ry12 had decreased OC activity and were partially protected from age-associated bone loss. P2ry12–/– OCs
exhibited intact differentiation markers, but diminished resorptive function. Extracellular ADP enhanced
OC adhesion and resorptive activity of WT, but not P2ry12–/–, OCs. In platelets, ADP stimulation of P2RY12
resulted in GTPase Ras-related protein (RAP1) activation and subsequent αIIbβ3 integrin activation. Likewise,
we found that ADP stimulation induced RAP1 activation in WT and integrin β3 gene knockout (Itgb3–/–) OCs,
but its effects were substantially blunted in P2ry12–/– OCs. In vivo, P2ry12–/– mice were partially protected from
pathologic bone loss associated with serum transfer arthritis, tumor growth in bone, and ovariectomy-induced
osteoporosis: all conditions associated with increased extracellular ADP. Finally, mice treated with the clinical
inhibitor of P2RY12, clopidogrel, were protected from pathologic osteolysis. These results demonstrate that
P2RY12 is the primary ADP receptor in OCs and suggest that P2RY12 inhibition is a potential therapeutic
target for pathologic bone loss.
Introduction
Osteoclasts (OCs) are multinucleated myeloid lineage cells that are the
principal source of bone resorptive activity (1). Enhanced OC activity, bone loss, and fractures are associated with rheumatoid arthritis, postmenopausal osteoporosis, and bone metastases (2). Modulation of osteoclastic bone resorption represents an attractive point
of therapeutic intervention for the treatment of such conditions.
Numerous purinergic G-protein–coupled nucleotide receptors
are expressed in the bone microenvironment (3, 4). For example,
uridine diphosphate–activated (UDP-activated) P2Y6 has been
reported to increase NF-κB activation and OC survival (5), while
P2Y2 (an ATP receptor) expression on osteoblasts (OBs) blocks
bone mineralization (6, 7). Hoebertz et al. demonstrated that
extracellular adenosine diphosphate (ADP) stimulates OC bone
resorption in vitro, in part through the ADP receptor P2Y1 on OC
(8); however, other ADP receptors, including purinergic receptor
P2Y, G protein coupled, 12 (P2RY12), which is the target of the
widely prescribed antiplatelet drug clopidogrel (Plavix), have not
been evaluated for their roles in osteoclastic bone resorption.
Authorship note: Xinming Su and Desiree H. Floyd contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(10):3579–3592. doi:10.1172/JCI38576.

P2RY12, initially identified as the Gαi-coupled ADP receptor on
platelets (9), plays a critical role in thrombus stability in vivo (10).
The active metabolite of clopidogrel directly binds and irreversibly inhibits P2RY12 signaling, resulting in diminished platelet
activation and aggregation, due in large part to reduced insideout activation of the critical platelet integrin αIIbβ3 (11). Mice with
targeted disruption of the P2ry12 gene (P2ry12–/–) have prolonged
bleeding times associated with a decrease in platelet function (9,
10). P2RY12 signaling via Gαi results in Ras-related protein (RAP1)
GTPase-mediated activation of αIIbβ3, which is required for platelet activation and aggregation (9, 12–17). RAP1 GTPase-mediated
activation of β3-containing integrins has been shown to be necessary for cell adhesion, spreading, and migration (13, 18–20).
Importantly, β3 integrins also play critical roles in OC formation,
adhesion, and bone resorption (21). We hypothesized that ADP
ligation of P2RY12 would affect OC function in part through activation of αvβ3 integrin (22–25).
P2RY12 has been shown to be biologically important in microglial cells, vascular smooth muscle cells, and brain endothelial
cells (26–28) as well as in the growth of tumor cell lines (29, 30).
P2RY12 is not expressed in splenic macrophages or in human alveolar macrophages and is expressed at negligible or very low levels
in most other tissues (9, 31–33). Extracellular nucleotides such as
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ADP/ATP are released during tissue injury, inflammation, tumor
growth, and aging (34–38). ADP released during neuronal injury
induces the P2RY12-dependent chemotaxis of microglia to the
injury site, allowing for neuroprotective activity (31, 39, 40). We
sought to examine the role of P2RY12 within the bone microenvironment during pathologic conditions associated with increases
in extracellular ADP/ATP (36, 41–43).
We found that P2ry12–/– mice exhibited decreased OC activity
in vivo and were partially protected from aging-related bone loss.
P2ry12–/– macrophages displayed reduced bone resorptive activity
in response to extracellular ADP. Furthermore, extracellular ADP
induced RAP1 activation in a P2RY12-dependent manner. Finally,
genetic or pharmacologic inhibition of P2RY12 partially protected mice from bone loss associated with arthritis, tumor growth
in bone, and estrogen loss. These data suggest that antagonism
of P2RY12 was sufficient to decrease OC function in vivo and
decrease pathologic bone loss.
Results
P2ry12–/– mice were protected from age-associated bone loss. Under nonpathologic conditions, young mice (aged 2 months) with germline
loss of the ADP receptor P2RY12 (P2ry12–/–) had no significant
changes in bone mineral density (BMD), trabecular bone volume
(BV/TV; Supplemental Figure 1, A–C; supplemental material
available online with this article; doi:10.1172/JCI38576DS1), trabecular bone formation rate (BFR) (Supplemental Figure 1, F–H),
or OC or OB numbers (Supplemental Figure 1, I–M and Supplemental Methods) compared with WT littermates. In contrast,
8-month-old P2ry12–/– mice showed significantly increased BV/
TV and BMD in the primary and secondary spongiosa of the tibia
compared with WT littermate controls (Figure 1, A–C). Notably,
P2ry12–/– mice displayed trabecular bone extending into the diaphysis. Histological analyses of tibiae showed a decreased OC surface
per bone surface in P2ry12–/– mice, but no detectable change in
OB number, OB surface per bone surface (Figure 1, I–M), or BFR,
suggesting that decreased bone resorption predominantly contributed to the increased bone density in older P2ry12–/– mice.
Bone turnover markers in 2- and 8-month-old mice were evaluated. In 2-month-old mice, both serum carboxy-terminal collagen
crosslinks (CTX) (a marker of OC resorption) and serum N-terminal propeptide of type I procollagen (P1NP) (a marker of bone
formation) were significantly decreased in P2ry12–/– mice (Supplemental Figure 1, D and E) despite no significant difference in BV/
TV, suggesting that both potential effects of P2RY12 disruption
on bone resorption and formation were balanced and resulted in
no significant net change in bone volume. At the 8-month time
point, serum CTX was significantly decreased in P2ry12–/– (Figure
1D), while serum P1NP was equivalent to that of WT littermates
(Figure 1, E–H), consistent with the findings of increased BV/TV
in P2ry12–/– mice without significant differences in BFR. CTX and
P1NP levels reflect the bone resorption and formation activities
happening at a discrete point in time and may reflect transient
effects of P2RY12 on both OC and on OB, whereas BV/TV by μCT
demonstrates cumulative effects on total bone, which point to
defective bone resorption as a predominant consequence of P2ry12
disruption in 8-month-old mice.
ADP enhanced ex vivo OC bone resorption primarily through the
P2RY12 receptor. As P2ry12–/– mice exhibited decreased OC activity in vivo (Figure 1, D and M), cell autonomous P2RY12 expression and function were evaluated during osteoclastogenesis.
3580

Expression of P2ry12 increased during ex vivo differentiation
from BM macrophages (BMMs) (day 0) to Tartrate-resistant acid
phosphatase–positive (TRAP+) OCs (day 3) and remained higher
than BMMs in mature multinucleated OCs (day 5) (Figure 2A).
Immunofluorescence confirmed that WT, but not P2ry12–/–, OC
cultures expressed P2RY12 (Supplemental Figure 2A). Furthermore, WT cells responded to ADP with a decrease in intracellular
cAMP (Supplemental Figure 2B), but P2ry12–/– cells or cells treated
with P2RY12 inhibitor did not respond (Supplemental Figure 2,
B and C, and Supplemental Methods). Under standard culture
conditions, without ADP stimulation, P2ry12–/– BMMs differentiated into multinucleated TRAP-positive OCs (Figure 2B), and no
significant differences compared with WT cells in OC differentiation markers on days 1–5 (Figure 2, C–E, Supplemental Figure 3,
and Supplemental Methods; all primers are listed in Supplemental Table 1), macrophage proliferation, or OC apoptosis (data
not shown) were observed. Functionally, P2ry12–/– cells exhibited
decreased formation of bone resorption pits compared with WT
cells (Figure 2, H–J). ADP stimulation resulted in increases in day 3
OC number and day 6 bone pit area in WT, but not P2ry12–/–, OCs
(Figure 2, F–J). We performed these experiments using BMMs from
2- and 8-month-old mice and obtained similar results. Because
ADP binds both P2Y1 and P2RY12 with high efficiency and potency, with EC50 values in platelet assays of 1 μM and 60 nM, respectively (9, 44), we determine whether P2Y1 could compensate for
the loss of P2RY12 expression in OCs. Expression of P2Y1 was not
different between WT and P2ry12–/– cells and was not significantly
induced during OC differentiation (Supplemental Figure 4A). In
both WT and P2ry1–/– cells, ADP stimulation increased actin ring
and resorption pit formation on bone (Supplemental Figure 4,
B–G), suggesting that ADP signaling through P2Y1 did not exert a
significant effect on OC function and that P2RY12 is a major ADP
receptor in OCs. These results demonstrate that P2ry12–/– cells
exhibited intact OC differentiation, but decreased resorptive function, and that extracellular ADP can enhance osteoclastogenesis
and OC function primarily through P2RY12.
P2ry12–/– OCs showed impaired ADP-mediated actin ring responses
and RAP1 activation. In platelets, ADP stimulation through the
P2RY12 receptor acts upstream of the integrin α IIbβ 3, resulting in platelet adhesion and aggregation (9, 44–46). Because
OC adhesion via αvβ3 integrin and other integrins is necessary
for actin ring formation and bone resorption (47), we hypothesized that P2RY12 ligation will act upstream of αvβ3, resulting in enhanced OC actin ring formation. ADP enhanced actin
ring formation on bone in WT, but not P2ry12 –/–, cells (Figure 3, A and B). These results suggest that extracellular ADP
and P2RY12 signaling can modulate actin ring response to
extracellular ADP in OCs.
RAP1 GTPase in platelets is activated downstream of P2RY12mediated activation of Gβγ and PI3K and is critical for inside-out
activation of platelet integrin αIIbβ3 (14, 17, 48, 49). RAP1 also
affects the activation of the related integrin αvβ3 in metastatic
melanoma cells (50). We found that extracellular ADP resulted
in a potent induction of activated GTP-bound RAP1 in WT preOCs that was blunted in P2ry12–/– cells (Figure 3, C and D). ADPmediated RAP1 activation was intact in integrin β3 gene knockout
(Itgb3–/–) pre-OCs (Figure 3, C and D), suggesting that P2RY12 is
upstream of β3 integrin signaling in pre-OCs as it is in platelets.
The ADP-mediated RAP1 activation in pre-OC was blocked by PI3K
inhibitors (wortmannin or LY294002), but not by chelation of cal-

The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012

Downloaded on October 17, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/38576

research article

Figure 1
P2ry12–/– mice were protected from age-associated bone loss. (A–C) The primary and secondary spongiosa of the tibias of age- and sex-matched
WT and P2ry12–/– littermate mice were analyzed by μCT scanning. (A) Representative 3D reconstructions of trabecular bone. Scale bar: 200 μm.
(B) Calculation of BV/TV and (C) BMD. Tb, trabecular bone. (D and E) Serum concentration of CTX and P1NP measured by ELISA. (F) Bone
formation was visualized by calcein (first) and alizarin red (second) double-labeling and visualized in the trabecular bone. Scale bars: 200 μm.
MAR and BFR are shown (G and H). Bone histology, representative TRAP staining (I). Scale bar: 300 μm. (J–M) Quantification of OB and OC
cells in the primary and secondary spongiosa of the femur. OC number and OC surface per bone surface, OB number and OB surface per bone
surface are shown. Data represent mean ± SD. n = 6. *P < 0.05; **P < 0.01; ***P < 0.001.

cium or inhibitors of adenylate cyclase or PKA (Figure 3E). Furthermore, the absence of P2RY12 did not result in significant differences in the mRNA expression of RAP1 isoforms, RAP1 guanine
nucleotide exchange factors (GEFs), or GTPase-activating proteins
(GAPs) during OC differentiation (Supplemental Figure 6). These
data suggest that the decreased RAP1 activity in P2ry12–/– pre-OCs
was likely due to lack of signaling via P2RY12 rather than changes
in the expression of genes encoding RAP1 regulatory factors.
Because M-CSF can induce PI3K activation and can rescue the
adhesion/spreading defect in β3 integrin–deficient OCs (51) and
can enhance OC survival (52), we evaluated M-CSF induction of
RAP1 activation in both P2ry12–/– and β3 integrin–null cells. Treatment of pre-OCs with M-CSF resulted in a rapid and sustained
increase in RAP1 activation that was similar in WT and Itgb3–/– preOCs, but was delayed in P2ry12–/– cells (Supplemental Figure 5, A
and B). ADP or M-CSF also activated RAP1 in human OCs generated from peripheral blood mononuclear cells (data not shown). In

agreement with ADP treatment (Figure 3, C–E), M-CSF–mediated
RAP1 activation in pre-OCs was decreased by inhibitors of PI3K,
but not by inhibitors of adenylate cyclase or PKA or by chelation
of calcium (Supplemental Figure 5C). These data demonstrate
that ADP- and M-CSF–mediated RAP1 activation is downstream
of PI3K and may be mediated in part through P2RY12 signaling
in OCs. Taken together, these results show that the P2RY12 receptor was an upstream regulator for activation of RAP1 in pre-OCs.
P2ry12–/– mice had decreased arthritis-associated bone loss. Serum
transfer arthritis (STA) is a well-characterized model of inflammatory bone loss that phenocopies the osteolysis associated with
rheumatoid arthritis (53). In STA, serum from arthritic K/BxN
mice, which contain high levels of antibodies against the self antigen glucose-6-phosphate isomerase, is injected intraperitoneally
into naive mice, causing joint-centered inflammation and local
OC-mediated bone erosion. WT and P2ry12–/– mice exhibited
similar clinical inflammatory responses, as measured by paw and
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Figure 2
ADP enhances ex vivo OC bone resorption primarily through the P2RY12 receptor. (A) Quantitative real-time PCR of P2ry12 expression on day 0
through day 5 of OC differentiation. (B) WT and P2ry12–/– OCs stained for the OC marker protein TRAP on days 3–5 of OC differentiation. Scale bar:
300 μm. (C–E) Quantitative real-time RT-PCR of OC differentiation markers; nuclear factor of activated T cells, cytoplasmic 1α (Nfatc1α), TRAP, and
cathepsin K (Ctsk), normalized to levels of gapdh, comparing WT (black bars) and P2ry12–/– (white bars) cells on days 0–5 of OC culture. (F) WT and
P2ry12–/– macrophages were cultured with 50 ng/ml M-CSF and 50 ng/ml RANKL and treated with or without 1 μM ADP for 3 days. Day 3 OC culture
was stained for the OC marker protein TRAP. Scale bar: 300 μm. (G) Quantitation of OC number (≥ 3 nuclei). (H) BMMs derived from 8-month-old WT or
P2ry12–/– mice were cultured with RANKL and MCSF on bone slices for 5 days. ADP was added at a final concentration of 1 μM where indicated. Scale
bar: 100 μm. (I and J) Quantification of bone pit area. Data represent mean ± SD. n = 3 per condition. *P < 0.05; **P < 0.01.
3582
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Figure 3
P2ry12–/– OCs showed impaired ADP-induced RAP1 activation. (A and B) BMMs derived from 8-month-old WT or P2ry12–/– mice were cultured
with RANKL and MCSF on bone slices for 5 days. ADP was added at a final concentration of 1 μM where indicated. (A) Actin ring formation was
determined by immunofluorescence following Rhodamine-phalloidin staining. Scale bar: 100 μm. Actin ring area was quantitated in B. (C) Western
blots of total RAP1 and RAP1-GTP in ADP-stimulated pre-OCs (day 3 OC culture). WT and P2ry12–/– pre-OCs were treated with ADP (1 μM) for
0–15 minutes. Total RAP1 was detected in total cell lysate, while activated RAP1 (RAP1-GTP) was pulled down by using Ral GDS-RBD–labeled
agarose beads. (D) Densitometry of GTP-RAP1 induction versus WT time 0. (E) WT pre-OCs were treated with or without 1 μM ADP and BAPTA,
ddADO, H89, or inhibitors of PI3K (wortmannin or LY294002), as indicated. Total RAP1 and activated RAP1 were detected as above. Data represent mean ± SD and are representative of at least 3 experiments. **P < 0.01.

ankle swelling (Figure 4, A and B). However, CTX levels indicative
of bone resorption were significantly decreased in P2ry12–/– mice
compared with WT (Figure 4C). Histological analysis of ankle
joints showed no differences in numbers of TRAP+ OC per bone
surface, but did show significantly decreased OC surface per bone
surface (Figure 4, D–G) and a decrease in TRAP+ area over total
tissue area in P2ry12–/– mice. This result mirrors the in vitro findings (Figure 2, F–H) that the P2ry12–/– OCs specifically showed
decreased function without a significant change in number. Finally, WT mice with STA exhibited a significant decrease in BMD in
the calcaneal bones as measured by μCT compared with P2ry12–/–
mice (Figure 4, H and I). These data demonstrate that P2ry12–/–
mice were partially protected from arthritis-associated bone loss
despite the development of joint inflammation.
Genetic and pharmacologic inhibition of P2RY12 protected mice from
tumor-associated bone loss. OC recruitment and activation play a
critical role in tumor-associated bone loss, pathologic fracture,
and pain associated with bone metastases (2). Syngeneic osteolytic B16-F10 melanoma cells were inoculated directly into 1 tibia

and PBS injected into the contralateral tibia of 8-week-old WT and
P2ry12–/– mice. The tumor burden between WT and P2ry12–/– mice
was not significantly different as measured by bioluminescence
imaging (BLI) (Figure 5, A and B); however, μCT showed that WT
mice displayed significant trabecular bone loss in the tumor-bearing tibiae, whereas P2ry12–/– mice maintained bone volume equivalent to that in the saline-injected tibiae (Figure 5, C and D). Histomorphometric evaluation revealed a significant increase in OC
number and surface in tumor-bearing WT tibiae compared with
saline-injected tibiae, whereas OC parameters were equivalent in
both P2ry12–/– bones (Figure 5, E and F), suggesting that P2RY12
was involved in tumor-induced recruitment of OC.
We next examined the effects of pharmacologic P2RY12 inhibition in a model of bone metastasis. Clopidogrel, a specific
and irreversible P2RY12 antagonist, is commonly prescribed to
inhibit platelet aggregation in coronary artery disease, peripheral vascular disease, and cerebrovascular disease (11, 54). Bone
metastases were established using a tumor model of intracardiac injection of the syngeneic osteolytic 4T1-GFP-FL murine
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Figure 4
P2ry12–/– mice had decreased arthritis-associated bone loss. STA was induced in 6-week-old
WT (n = 8) or P2ry12–/– (n = 6) mice by injection of K/BxN serum on days 0 and 2. (A) Hind
paw thickness was measured bilaterally daily.
(B) Inflammation area over total ankle area was
determined by measuring inflammatory tissue
area on hematoxylin staining of ankle tissue.
(C) Serum CTX assay to measure OC activity
on day 11. n = 5 per group. (D–F) Histological
analyses of ankle with TRAP staining. Scale
bar: 100 μm. Scale bar: 100 μm. Quantitation
of TRAP+ area (E), OC number (N.) per bone
surface (F), and OC surface per bone surface
(G) in the boxed ROI. (H and I) Representative
μCT 3D reconstructions of hind limb ankle joints
11 days following STA induction and calcaneal
bone BMD are shown. Scale bar: 300 μm. Data
represent mean ± SD. *P < 0.05; **P < 0.01.

mammary carcinoma cell line into immunocompetent BALB/c
mice. Beginning 2 days after tumor inoculation, clopidogrel
(30 mg/kg) or vehicle was administered in the drinking water
for 9 days. We did not observe any change in body weight, fur
ruffling, general activity, and appearance of mice that were
treated with clopidogrel. As expected, mice that received clopidogrel had an increased bleeding time. Clopidogrel administration did not affect tumor burden (Figure 6, A and B), but
increased tibial BV/TV and BMD compared with vehicle-treated
tumor-bearing mice (Figure 6, C and D). While there was no
significant decrease in OC number, clopidogrel treatment significantly reduced the OC surface per trabecular bone surface
(Figure 6, E–G). Interestingly, clopidogrel treatment was associated with increased tibial BV/TV and BMD and decreased CTX
in non–tumor-bearing 6-week-old WT mice (Supplemental Fig3584

ure 7, A–D). Together, these results demonstrate that P2ry12–/–
mice and clopidogrel-treated WT mice were protected from
tumor-induced osteolysis through effects on OCs.
P2RY12 antagonism partially protected mice from ovariectomy-induced
bone loss. Because P2ry12–/– mice were partially protected from ageassociated bone loss (Figure 1), we evaluated whether the absence
of P2RY12 could prevent bone loss in a model of estrogen deficiency–induced osteoporosis. Ovariectomy (OVX) was performed on
P2ry12–/– and WT littermates at 14 weeks, an age at which no significant differences in baseline BV/TV were observed. At 2 and 5 weeks
after OVX, P2ry12–/– mice had lost significantly less tibial bone
mass than WT controls (Figure 7A). Serum CTX was significantly
lower in P2ry12–/– mice after OVX, whereas serum P1NP (Figure
7B) and BFR (Figure 7, C and D) were not significantly changed. In
agreement, histomorphometric analysis showed that the number
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Figure 5
Genetic inhibition of P2RY12 protected mice from tumor-associated bone loss. (A and B) 1 × 104 B16-FL tumor cells (right leg) or PBS (control,
left leg) were injected directly into the tibia (n = 6 per group). (A and B) The tumor burden in hind limbs was measured by BLI. (C and D) BV/TV
and BMD in the primary and secondary spongiosa of PBS-injected or tumor-bearing tibia were analyzed by μCT. (E) TRAP-stained tibial sections
(×4) of WT (top) and P2ry12–/– mice (bottom) 10 days after tumor injection. T, tumor; M, marrow. TRAP+ staining (dark red areas) indicates OC
presence. Scale bar: 300 μm. (F) OC number and surface per bone surface in the primary and secondary spongiosa of the tibia are shown in
saline-injected tibia (S) (black bars) and tumor-injected tibia (T) (white bars). Data represent mean ± SD. n = 6. *P < 0.05.

and surface area of OCs were significantly higher in the femoral
bones of WT mice compared with P2ry12–/– mice, whereas OB number and surface area were not significantly different between WT
and P2ry12–/– mice following OVX (Figure 7, E and F). BMD did
decline in P2ry12–/– mice after OVX by day 35, but to a lesser extent
than in WT mice. Together, these data suggest that P2ry12–/– mice
were partially protected from OVX-induced bone loss.
Likewise, pharmacologic inhibition of P2RY12 with clopidrogel (orally administered at 30 mg/kg/d) protected WT mice
from significant OVX-induced bone loss at day 14 compared
with sham surgery control (Figure 8A). At day 35, all OVX mice
experienced significant bone loss compared with sham controls;
however, clopidogrel-treated mice remained partially protected
from OVX-mediated bone loss compared with vehicle controls
(Figure 8B). At day 14, serum CTX and P1NP levels were elevated
in both OVX groups compared with sham groups, indicative of
increased bone turnover (Figure 8C); however, clopidogrel treatment significantly decreased CTX levels compared with vehicle,
demonstrating that P2RY12 antagonism blunted osteoclastic
bone resorption. While the overall extent of bone turnover was
decreased by day 35 after OVX, serum CTX levels remained significantly higher in vehicle-treated mice that had undergone OVX
compared with sham-treated mice, while clopidogrel treatment

decreased the CTX levels of OVX mice to a point equivalent to
that of the sham control group (Figure 8C). Serum P1NP levels
showed no significant difference between groups at day 35 (Figure 8C). Clopidogrel treatment blunted the increase in OC number and OC surface per bone surface observed in vehicle-treated
mice following OVX at day 14 and day 35 (Supplemental Figure
8, A and B, and Figure 8, D and E). OB number and surface per
bone surface were not significantly different between clopidogrel
and vehicle treatment (Supplemental Figure 8, A and B). Likewise,
although OVX itself did cause a decrease in BFR at day 14, but
not day 35, P2RY12 antagonism with clopidogrel did not alter
this response compared with vehicle (Supplemental Figure 8,
C–F). In agreement with results obtained with genetic disruption
of P2ry12, these data demonstrate that pharmacologic blockade
of P2RY12 partially protected mice from OVX-induced bone loss
and that the protection was predominantly from a blunting of
OC-mediated resorption.
Discussion
In this report, we demonstrate what we believe is a novel role for
the ADP receptor P2RY12 in the function of bone-resorbing OCs,
particularly in preclinical models of pathologic bone loss associated with postmenopausal osteoporosis, rheumatoid arthritis,
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Figure 6
Pharmacologic inhibition of P2RY12 protected mice from tumor-associated bone loss. 4T1-GFP-FL tumor cells were directly injected into the left
cardiac ventricle of WT Balb/c mice (n = 12 per group). Clopidogrel treatment (30 mg/kg/d in drinking water) was begun 2 days after tumor cell
injection and continued for 9 days. (A) The tumor burden in hind limbs measured by BLI and (B) representative pictures of BLI at day 11. (C and
D) BV/TV and BMD of the tibia of tumor-bearing mice at day 11 were analyzed by μCT. (E) TRAP-stained hind limb sections at day 11 after tumor
injection and vehicle or clopidogrel treatment. TRAP+ staining (dark red areas) indicates OC presence. Scale bar: 300 μm. OC number and surface
in the primary and secondary spongiosa of the tibia are shown (F and G). Data represent mean ± SD. *P < 0.05; **P < 0.01.

and bone metastases. We demonstrate that antagonism with the
FDA-approved P2RY12 inhibitor, clopidogrel, decreased bone loss
in murine models of osteoporosis and tumor-associated bone loss.
These data suggest that clopidogrel or novel ADP and P2RY12targeted therapies could be clinically evaluated in disease states
characterized by excessive bone resorption.
The phenotypic overlap between P2ry12–/– and Itgb3–/– mice is
striking. Itgb3–/– mice have a severe platelet aggregation defect and
have increased bone mass with decreased OC function (25, 47, 55).
P2ry12–/– mice display similar defects in platelet aggregation (10)
and osteoclastic bone resorption, albeit both are milder than those
of the Itgb3–/– mice. Similarly to Itgb3–/–, P2ry12–/– mice also developed increased trabecular bone mass with aging due to impaired
OC function and demonstrated protection from tumor-induced
bone loss, again less severe than in the Itgb3–/– mice (22, 47). These
results suggest that P2RY12 and β3 integrin may lie in the same
signaling pathway necessary for OC formation and function, as
they do for platelet adhesion.
Decreased adhesion, actin ring formation, migration, and
resorption of Itgb3–/– OCs have been reported (23). Adhesion is
critical to the formation of actin rings in OCs and the sealing zone
necessary for directional delivery of bone-resorbing enzymes and
3586

acids (1, 47, 56). Because P2RY12 has previously been shown to
play a role in adhesion in platelets and microglial cells (10, 29) and
is required for microglial migration toward ADP (26, 31, 57), we
evaluated its role in actin ring responses. Accordingly, we report
a decrease in ADP-enhanced actin ring formation on bone by
P2ry12–/– cells. We hypothesized that P2RY12 acts upstream of β3
integrin through a GTPase-related mechanism in OCs similar to
that in platelets and that RAP1 GTPase plays an important role in
this signaling pathway. In addition to its typical Gαi-coupled roles,
P2RY12 is known to couple to the Gβγ portion of the G protein
heterotrimer that activates PI3K, Akt, and eventually RAP1, leading to integrin activation in platelets (12–15, 17, 58–62). We found
that RAP1 activation was downstream of P2RY12 in pre-OCs and
that this activation was ADP dependent.
Interestingly, β3 integrin–null OCs had intact ADP-induced
RAP1 activation, suggesting that β3 integrins are downstream of
P2RY12 signaling. P2Y1, another Gαq-coupled ADP receptor, is also
expressed by OC lineage cells; however, our data that responses to
ADP were impaired in P2ry12–/– but not P2ry1–/– cells suggest that
P2RY12 is necessary for the majority of ADP-dependent RAP1 activity in OC. We cannot rule out that P2Y1 may cooperate with P2RY12
during osteoclastogenesis in situations associated with increased
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Figure 7
P2ry12–/– mice were partially protected from OVX-induced bone loss. OVX was performed on 14-week-old P2ry12–/– and WT littermates (n = 5
per group). (A) BV/TV and BMD were measured in the primary and secondary spongiosa of the tibia of live animals viva CT scanning prior to
and at days 14 and 35 following OVX. (B) Serum concentration of CTX and P1NP measured by ELISA. (C) Bone formation was visualized by
calcein (first) and alizarin red (second) double-labeling and visualized in the trabecular bone. Representative photographs: original magnification, ×2.5, scale bar: 300 μm; original magnification, ×20, scale bar: 50 μm. (D) MAR and BFR were measured. (E) TRAP-stained hind limb sections after OVX. Scale bar: 300 μm. (F) Quantification of OC and OB cells in the primary and secondary spongiosa of the femur. Data represent
mean ± SD. n = 5. *P < 0.05.

extracellular ATP/ADP. Likewise, RAP1 activation can also modulate outside-in integrin signaling, which is critical to OC function
(12, 24, 63). Taken together, our data suggest that ADP-mediated
RAP1 activation occurs in OC and is largely dependent on P2RY12.

In addition to RAP1, P2RY12 may also be upstream of other
GTPases, such as Rac or Cdc42, which are also critical to OC function (63, 64). The potentially varying role of different purinergic
receptors and RAP1 in OCs is currently under investigation. We
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Figure 8
P2RY12 antagonism partially protected mice from OVX-induced bone loss. 14-week-old WT C57BL/6 mice underwent OVX (n = 8) or
sham operation (sham) (n = 10) and were treated with clopidogrel (30 mg/kg/day) or vehicle-control in drinking water for 2 or 5 weeks.
Tibias from sham-operated and OVX mice were examined by μCT. (A and B) BV/TV in the primary and secondary spongiosa of the tibia
after OVX. (C) Serum concentration of CTX and P1NP measured by ELISA. (D) TRAP-stained hind limb sections after OVX. Scale bar:
300 μm. (E) Quantification of OC and OB cells 35 days after OVX. OC number (N.OC) per bone surface (N.OC/BS) and OB number per
bone surface (N.OB/BS) in the primary and secondary spongiosa of the femur. Data represent mean ± SD. n = 5. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.

cannot conclude that the activation of P2RY12 yields activation
of only β3-containing integrins, since RAP1 activity is upstream of
many integrin heterodimers (12, 14, 20, 49). We propose that activation of specific integrins by P2RY12 and other purinergic receptors may exist at different phases of OC formation, such as fusion
and migration; this hypothesis will be tested in future studies.
Our studies demonstrated that P2RY12 exerts its most
prominent effects on bone during pathological situations in
which extracellular ATP would be increased due to ongoing tissue damage and repair. Extracellular ATP can be degraded into
ADP by extracellular dephosphorylating enzymes; therefore,
the extracellular ADP concentration is positively corelated with
extracellular ATP levels. Tumor cells are known to establish a
microenvironment containing more than 100 μM extracellular
ATP, whereas ATP concentration is undetectable in healthy tissues (36). Likewise, the ATP concentration in synovial fluid from
patients with rheumatoid arthritis is substantially elevated at
50 nM, but undetectable in normal joint fluids (43). Thus, under
normal physiologic conditions, there is a minimal concentration of extracellular ATP in tissues and blood. Thus, the minimal
effects on in vivo bone mass observed in healthy 2-month-old
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P2ry12–/– mice may be attributed to low extracellular ADP/ATP
concentrations present under these conditions. In contrast, the
increased amounts of bone remodeling and tissue repair associated with aging skeletons and organs likely release ATP, resulting
in increased P2RY12 signaling, similar to that occurring in the
presence of tumor or inflammatory stimuli. Under such conditions of aging (8-month-old mice) or pathology, we found that
the genetic absence or pharmacological inhibition of P2RY12
blunted OC function, resulting in a preservation of bone mass.
Interestingly, the administration of clopidogrel to non–tumorbearing 6-week-old mice, a time at which bone turnover (and thus,
likely extracellular ATP/ADP) is high due to skeletal growth, also
increased bone volume. However, drug administration to 16-weekold mice (sham surgery group in Figure 8), a time when peak bone
mass has already been mostly reached and thus turnover and ATP
release would be expected to be decreased, did not affect bone
mass. In experiments using both genetic and pharmacologic disruption of P2RY12, we observed the most protection from bone
loss after OVX occurred within the first 2 weeks. We hypothesize
that extracellular ADP levels are likely higher in the early time
points after OVX, but it is also possible that P2RY12 disruption
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could cause small sequential decreases in OB formation in the
later time points. Therefore, the clinical benefit of P2RY12 inhibition or antagonism may be strongest during the early/peak time
period after injury or pathology.
The dosage of clopidogrel used in the in vivo studies was 30
mg/kg/d, which, after species conversion, is higher than the standard 75 mg/d dosage used in humans. However, except for the
expected longer bleeding time, we did not observe any negative
effects on general health, such as weight, grooming behavior, and
activity level. There could be indirect effects on bone of high-dose
clopidogrel from effects on platelets and perhaps off-target effects.
Thus, it is possible that some of the bone effects from clopidogrel
may not be present or may be different at lower doses, and this will
be explored in future studies.
In the disease models examined here, the effects of P2RY12 on
osteolysis and bone resorption predominated, and P2RY12 genetic
deletion or pharmacological inhibition consistently yielded a net
increase in bone mass. However, we cannot rule out that P2RY12
may have subtle effects on bone formation and OB function. In
aging mice, we did not detect differences in OB number per bone
surface in P2ry12–/– and WT mice, but there probably was an absolute increase in OB number, given the higher BV/TV in P2ry12–/–
mice. Thus, the function of individual OBs could be decreased, but
this could have been balanced by the increased number to give a
constant P1NP. Notably, we did observe modest decreases in serum
markers of both bone formation and resorption in 2-month-old
P2ry12–/– mice, although there were no changes in BMD or BFR
in these young mice. This could be consistent with balanced and
coupled bone formation and resorption that would have no net
effect on bone volume. It is also possible that P2RY12 exerts a
transient effect on OB function that may be reflected by serum
P1NP at a single, discrete time point, but did not result in a measurable change in the cumulative BFR measured over a period of
5 days. Such transient versus cumulative measurements of OB
activity may also account for the observation of increased P1NP, yet
decreased BFR, observed 2 weeks following OVX (Figure 8 and Supplemental Figure 8). A detailed analysis of the vertebral and femoral bones throughout the life span of P2ry12–/– mice will be important. Taken together, it is possible that P2RY12 may decrease OB
function, but in the in vivo models that we evaluated, the OC dysfunction predominated, resulting in an overall increase in BV/TV.
The role of P2RY12 in OBs is under intense study.
It has been reported that purinergic signaling can modulate
platelet function, inflammation, and pathologic angiogenesis,
which could modulate bone cell function in certain disease states
(2, 22, 36, 65–68). Recent preclinical data is conflicting regarding
the role of clopidogrel in inflammation both dependently and
independently of its effects on platelets (36, 68). We found that
in the STA model, the amount of clinical inflammation as measured by paw swelling was similar between WT and P2ry12–/– mice.
However, we cannot rule out that differences in specific inflammatory cytokines did not exist between genotypes, causing effects
on pathologic osteolysis. Interestingly, β3 integrins play a critical
role in platelet function, OC function, inflammatory responses,
and pathologic angiogenesis (69, 70). It is possible that some of
the bone resorption effects in the disease models evaluated in our
P2RY12 studies could in part be due to non–cell-autonomous
effects of P2RY12 signaling on neoangiogenesis, platelet activation, and/or inflammation. It has been reported that platelet
defects in a mouse model of von Willebrand disease had increased

bone mass (71). We have previously reported that mice with conditionally deleted β3 integrin in platelets had normal bone mass
despite severe platelet aggregation defects; conversely, mice with
conditional deletion of β3 integrin in myeloid/OC lineage cells had
osteosclerosis and increased bone mass despite normal platelet
function (72), suggesting that defective platelet function does not
necessarily modulate bone mass.
Currently, there are no prospective clinical data on BMD in
patients using clopidogrel. Interestingly, a population-based epidemiological study reported that the use of platelet inhibitors
aspirin and dipyridamole was associated with increased risk of
osteoporotic fractures, but this association was not observed with
clopidogrel (73). Clinical studies evaluating the effects on bone in
patients receiving clopidogrel or trials of clopidogrel in patients
with excessive bone resorption are warranted to determine whether clopidogrel or other novel ADP and P2RY12-targeted therapies (11, 67, 74) could have a role as in the treatment of disease
states characterized by excessive bone resorption. We propose that
P2RY12 targeting would likely only have effects on bone during
localized increases in extracellular ADP that can occur during tissue damage, inflammation, and cancer, with little effects on normal systemic bone turnover. Our data suggest that antagonism of
the ADP receptor, P2RY12, using currently available drugs could
represent a new approach to preventing pathologic bone loss.
Methods
Mice. WT, P2ry12 –/– (10), and Itgb3 –/– mice (75) on a pure C57BL/6
background were housed under pathogen-free conditions according to
the guidelines of the Division of Comparative Medicine, Washington
University School of Medicine. Unless noted, all mice were used at 6 to
10 weeks of age. P2ry1–/– BM cells (BMCs) were provided by Christian
Gachet (Université de Strasbourg, Strasbourg, France) (76).
Micro-computed tomography. Tibial metaphyses were scanned by microcomputed tomography (μCT) (μCT-40; Scanco Medical). The trabecular
region from forty 2D slices (0.8 mm) in the primary and secondary spongiosa of the tibia was selected using contours inside the cortical shell on
each 2D image, with the growth plate as a marker to determine a consistent
location to start analysis. A 3D cubical voxel model of bone was built, and
calculations were made for BV/TV and apparent BMD (calibrated against
a hydroxyapatite phantom). A threshold of 300 (out of 1,000) was used to
differentiate trabecular bone from nonbone.
Serum CTX and P1NP assays. CTX and P1NP were measured in fasting
serum using ELISA systems (Immunodiagnostic Systems Inc.).
OC culture assay. To generate primary BMMs, whole BM was extracted
from the femurs and tibias of mice and plated in petri dishes in α-MEM
medium containing 10% fetal bovine serum and M-CSF–containing CMG14-12 cell culture supernatant (50 ng/ml). For OC differentiation assays,
BMMs were plated at 2 × 104 per well in 48-well cell culture plates and fed
daily with osteoclastogeneic medium (α-MEM containing 10% FBS, CMG14-12 supernatant [50 ng/ml], and GST-RANKL [50 ng/ml]) for 3 to 6 days,
as previously described (77). Then, 1 μM ADP (Sigma-Aldrich) was added
daily to cultures as indicated. TRAP staining was performed according to
the manufacturer’s instructions (Sigma-Aldrich). The number of TRAP+
OCs with 3 or more nuclei were counted using ImageJ software (NCBI).
In vitro bone resorption assay. Bone resorption assays were performed
as previously described (77). For actin ring staining, cells were cultured
on bovine bone slices in osteoclastogeneic medium with or without
1 μm ADP for 6 days. Cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, rinsed in PBS, and immunostained with
Alexa Fluor 488 phalloidin (Molecule Probes) or Rhodamine-phalloidin
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(Invitrogen). To quantify resorption lacunae, cells were removed from
bone slices, and bone slices were incubated with peroxidase-conjugated wheat germ agglutinin (WGA) (Sigma-Aldrich) and stained with
3,3′-diaminobenzidine (Sigma-Aldrich). Resorption area was determined
from five 4× fields using BioquantOsteo software (Bioquant) by an operator blinded to genotype.
RAP1 pull down assays and Western blotting. BMMs derived from 2-monthold mice and OCs were cultured as above; day 3 OCs (pre-OCs) were used
for experiments. After ADP (0–1 μm) or CMG-14-12 supernatant (100
ng/ml) treatment, cells were washed in PBS and harvested into Tris Lysis
Buffer (TLB) (50 mM Tris-HCl, pH 7.4, 500 mM NaCl, 1% NP40, 2.5 mM
MgCl2, and 10% glycerol) plus 1% Mammalian Protease Inhibitor Cocktail
(Sigma-Aldrich). As indicated, cells were also treated with PI3K inhibitor
(wortmannin or LY294002), inhibitor for adenylate cyclase (ddADO), or
PKA (H89), or by chelation of calcium (BAPTA). A sample of the supernatant was incubated with Ral GDS-RBD–labeled Agarose Beads (Upstate
Biotechnology) for 45 minutes at 4°C. After washing, bound RAP1-GTP
was released from the beads by boiling in 2× Laemmli reducing sample
buffer. Western blotting was used to detect total RAP1 and RAP1-GTP
using rabbit anti-RAP1a/1b antibody (Cell Signaling Technology Inc.),
secondary HRP-conjugated goat anti-rabbit IgG (Calbiochem), and
chemiluminescent substrates for HRP (SuperSignal; Thermo Scientific).
Densitometry, where appropriate, was performed using Quantity One
software ver. 4.5.1 (Bio-Rad).
STA. The STA model was described previously (53). Briefly, 6-week-old
WT and P2ry12–/– mice were used in this model; arthritis was induced by
injection of serum from arthritic K/BxN mice on days 0 and 2, and hind
paw thickness was measured bilaterally every day (n = 5 per group). On
day 11, hind limbs were fixed and scanned by μCT. Histologic sections of
the hind paw were also analyzed as in Bone histomorphometry. Inflammation
area over total ankle area was determined by measuring inflammatory tissue area on H&E staining of ankle tissue. TRAP+ area over total tissue area,
OC number, and OC surface per bone surface were measured by Bioquant
Osteo software (Bioquant Image Analysis Corp.) on TRAP-stained slices
of ankle tissue.
Image acquisition. Images of cells and isolated tibial, femoral, and calcaneal bones were taken with a Nikon Eclipse TE300 inverted microscope connected to a Magnafire camera model S99802 (Optronics). The ×4 Nikon
lens with numerical aperture 0.13, the ×10 Nikon lens with numerical aperture 0.30, or the ×40 Nikon lens with numerical aperture 0.60 was used.
Bone histomorphometry. Mouse hind limbs or tibias/femurs were fixed in
10% formalin for 24 hours and decalcified in 14% EDTA solution for 2
weeks (tibia and femur) or 3 weeks (hind limbs with soft tissue). Paraffinembedded sections were stained with H&E for OB parameter analysis or
stained with TRAP for OC parameter analysis within the primary and secondary spongiosa. Sections were analyzed by a blinded operator according
to a standard protocol using Bioquant Osteo V7 10.10 (Bioquant Image
Analysis Corp.).
Tumor and bone metastasis models. The B16-F10 C57BL/6 murine melanoma cell line (ATCC) was modified to express firefly luciferase (B16-FL) as
described (77). For intratibial injections, 1 × 104 B16-FL cells in 50 μl PBS
were injected into the right tibia, and PBS (50 μl) was injected into the left
tibia as an internal control (77). At day 9, tibias were fixed and decalcified
for histologic sections.
For intracardiac injections, the left ventricular chambers of 6-weekold female Balb/c mice were inoculated with 10 5 4T1 BALB/c triplenegative murine breast cancer cells labeled with GFP-firefly luciferase
gene (4T1-GFP-FL) (78) in 50 μl PBS as previously described (77). BLI
was performed on days 2, 7, 9, and 11 after inoculation. Treatment with
clopidogrel (30 mg/kg/d in drinking water) was begun 2 days after
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tumor cell injection. Mice underwent blinded necropsy on day 11 after
tumor cell injection, and tibias were fixed and analyzed by μCT. Mice
were discarded from the final analysis when the animal died before day
11 or necropsy showed a large mediastinal tumor indicative of injection
of tumor cells into the chest cavity. In order to have sufficient remaining
trabecular bone for histomorphometry analysis, all data were analyzed
from the tibia where areas of non–tumor-invaded bone were still present, since tumor burden is often higher in femurs, likely due to increased
marrow space.
BLI. For BLI of live animals, previously described mice were injected
intraperitoneally with 150 μg/g D-luciferin (Biosynth) in PBS, anesthetized with 2.5% isoflurane, and imaged with a charge-coupled device
(CCD) camera-based BLI system (IVIS 100; Caliper; exposure time 1–60
seconds, binning 8, field of view 12, f/stop 1, open filter, anterior side).
Signal was displayed as photons/s/cm2/sr (79). Regions of interest (ROI)
were defined manually around the legs using Living Image and IgorPro
Software (Version 2.50).
OVX. OVX or sham surgeries were performed as described in ref. 80
with the following modifications: 14-week-old female C57BL/6 mice or
P2ry12–/– mice were anesthetized using 2% isoflurane; ovaries were exposed
through an abdominal approach and removed by cauterization. The peritoneum and skin were sutured separately. Pain was managed by subcutaneous injection of 0.075 mg/kg bupernorphine followed by 1:30 dilution of
children’s liquid pain reliever (32 mg acetaminophen/ml) in the drinking
water for 2 days. Clopidogrel treatment (30 mg/kg/d in drinking water)
was begun 2 days after OVX.
Statistics. Data are shown as mean ± SD unless noted otherwise. All experiments were analyzed using 2-tailed unpaired Student’s t test for 2 groups
or 1-way ANOVA with Bonferroni’s post-hoc test for 3 or more groups by
Prism (GraphPad Software). P < 0.05 was considered significant.
Study approval. The study protocols were approved by the Washington
University Animal Studies Committee.

Acknowledgments
The authors wish to thank Steven Teitelbaum, F. Patrick Ross,
Roberta Faccio, Haibo Zhao, Thomas Baranski, Michael Tomasson,
Tiffany Foulks, and Viviana Cremasco for their valuable expert suggestions and criticism. We thank Crystal Idleburg for expert histology. We thank the Musculoskeletal Research Center for histology
and microCT (NIH AR057235) and the Molecular Imaging Center
for Bioluminescence Studies (P50 CA94056). Thank you to the St.
Louis Men Against Cancer and the Barnes Jewish Foundation for
support. D.H. Floyd, X. Su, A.C. Hirbe, M.C. Eagleton, S. Townsley,
J. Xiang, and K.N. Weilbaecher were supported by R01 CA097250;
D.H. Floyd and A.C. Hirbe were supported by hematology training
grant T32 HL007088; K. Wu was supported by the Howard Hughes
Medical Institute (HHMI); and L. Collins, D. Piwnica-Worms, O.
Uluckan, and M.A. Hurchla were supported by P50 CA94056. T.H.
Steinberg and D. Grabowska were supported by a VA Merit Review
Award. A. Hughes and M.J. Rogers were supported by grant 17285
from Arthritis Research UK.
Received for publication November 9, 2011, and accepted in
revised form July 26, 2012.
Address correspondence to: Katherine Weilbaecher, Washington
University School of Medicine, Division of Oncology, Campus
Box 8069, 660 South Euclid Avenue, St. Louis, Missouri 63110,
USA. Phone: 314.454.8858; Fax: 314.454.8973; E-mail: kweilbae@
dom.wustl.edu.

The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012

Downloaded on October 17, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/38576

research article
1. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–1508.
2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer.
2011;11(6):411–425.
3. Orriss I, et al. Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed). 2011;3:1038–1046.
4. Reyes JP, Sims SM, Dixon SJ. P2 receptor expression, signaling and function in osteoclasts. Front
Biosci (Schol Ed). 2011;3:1101–1118.
5. Korcok J, Raimundo LN, Du X, Sims SM, Dixon
SJ. P2Y6 nucleotide receptors activate NF-kappaB
and increase survival of osteoclasts. J Biol Chem.
2005;280(17):16909–16915.
6. Buckley KA, Hipskind RA, Gartland A, Bowler WB,
Gallagher JA. Adenosine triphosphate stimulates
human osteoclast activity via upregulation of
osteoblast-expressed receptor activator of nuclear
factor-kappa B ligand. Bone. 2002;31(5):582–590.
7. Orriss IR, et al. Extracellular nucleotides block
bone mineralization in vitro: evidence for dual
inhibitory mechanisms involving both P2Y2
receptors and pyrophosphate. Endocrinology.
2007;148(9):4208–4216.
8. Hoebertz A, Meghji S, Burnstock G, Arnett TR.
Extracellular ADP is a powerful osteolytic agent:
evidence for signaling through the P2Y(1) receptor
on bone cells. FASEB J. 2001;15(7):1139–1148.
9. Hollopeter G, et al. Identification of the platelet
ADP receptor targeted by antithrombotic drugs.
Nature. 2001;409(6817):202–207.
10. Andre P, et al. P2Y12 regulates platelet adhesion/
activation, thrombus growth, and thrombus
stability in injured arteries. J Clin Invest. 2003;
112(3):398–406.
11. Herbert JM, Savi P. P2Y12, a new platelet ADP
receptor, target of clopidogrel. Semin Vasc Med.
2003;3(2):113–122.
12. Bernardi B, et al. The small GTPase Rap1b regulates the cross talk between platelet integrin
alpha2beta1 and integrin alphaIIbbeta3. Blood.
2006;107(7):2728–2735.
13. Bertoni A, et al. Relationships between Rap1b,
affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J Biol Chem.
2002;277(28):25715–25721.
14. Kamae T, et al. Critical role of ADP interaction with
P2Y12 receptor in the maintenance of alpha(IIb)
beta3 activation: association with Rap1B activation. J Thromb Haemost. 2006;4(6):1379–1387.
15. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem.
2004;279(6):4186–4195.
16. Larson MK, et al. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood.
2003;101(4):1409–1415.
17. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF.
Activation of Rap1B by G(i) family members in
platelets. J Biol Chem. 2002;277(26):23382–23390.
18. Lorenowicz MJ, van GJ, de BM, Hordijk PL, Fernandez-Borja M. Epac1-Rap1 signaling regulates
monocyte adhesion and chemotaxis. J Leukoc Biol.
2006;80(6):1542–1552.
19. Lorenowicz MJ, Fernandez-Borja M, Kooistra
MR, Bos JL, Hordijk PL. PKA and Epac1 regulate
endothelial integrity and migration through parallel and independent pathways. Eur J Cell Biol.
2008;87(10):779–792.
20. Medeiros RB, et al. Protein kinase D1 and the beta
1 integrin cytoplasmic domain control beta 1 integrin function via regulation of Rap1 activation.
Immunity. 2005;23(2):213–226.
21. Feng X, et al. A Glanzmann‘s mutation in beta 3
integrin specifically impairs osteoclast function.
J Clin Invest. 2001;107(9):1137–1144.
22. Bakewell SJ, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad

Sci U S A. 2003;100(24):14205–14210.
23. Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell
attachment are controlled by beta3 integrin. J Cell
Biol. 2003;162(3):499–509.
24. Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005;208:88–105.
25. Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum
SL, Novack DV. Critical role of beta3 integrin in
experimental postmenopausal osteoporosis. J Bone
Miner Res. 2005;20(12):2116–2123.
26. Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue
K, Kohsaka S. Involvement of P2X4 and P2Y12
receptors in ATP-induced microglial chemotaxis.
Glia. 2007;55(6):604–616.
27. Simon J, et al. Characterization and channel
coupling of the P2Y(12) nucleotide receptor
of brain capillary endothelial cells. J Biol Chem.
2002;277(35):31390–31400.
28. Tolhurst G, Vial C, Leon C, Gachet C, Evans RJ,
Mahaut-Smith MP. Interplay between P2Y(1),
P2Y(12), and P2X(1) receptors in the activation of
megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a
fully functional model of platelet P2 receptor signaling. Blood. 2005;106(5):1644–1651.
29. Krzeminski P, Suplat D, Czajkowski R, Pomorski
P, Baranska J. Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in
long-term serum-deprived glioma C6 cells. FEBS J.
2007;274(8):1970–1982.
30. Mamedova LK, Gao ZG, Jacobson KA. Regulation
of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Biochem Pharmacol.
2006;72(8):1031–1041.
31. Haynes SE, et al. The P2Y12 receptor regulates
microglial activation by extracellular nucleotides.
Nat Neurosci. 2006;9(12):1512–1519.
32. Myrtek D, et al. Activation of human alveolar macrophages via P2 receptors: coupling to intracellular
Ca2+ increases and cytokine secretion. J Immunol.
2008;181(3):2181–2188.
33. Pausch MH, Lai M, Tseng E, Paulsen J, Bates B, Kwak
S. Functional expression of human and mouse
P2Y12 receptors in Saccharomyces cerevisiae. Biochem Biophys Res Commun. 2004;324(1):171–177.
34. Ravichandran KS. Find-me and eat-me signals
in apoptotic cell clearance: progress and conundrums. J Exp Med. 2010;207(9):1807–1817.
35. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol.
2011;11(3):201–212.
36. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F,
Pistoia V, Di VF. Increased level of extracellular
ATP at tumor sites: in vivo imaging with plasma
membrane luciferase. PLoS One. 2008;3(7):e2599.
37. Moreira PI, Santos MS, Moreno AM, Seica R,
Oliveira CR. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with
aging and amyloid-beta exposure. Diabetes. 2003;
52(6):1449–1456.
38. Schroder K, Tschopp J. The inflammasomes. Cell.
2010;140(6):821–832.
39. Honda S, et al. Extracellular ATP or ADP induce
chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci. 2001;21(6):1975–1982.
40. Kurpius D, Nolley EP, Dailey ME. Purines induce
directed migration and rapid homing of microglia
to injured pyramidal neurons in developing hippocampus. Glia. 2007;55(8):873–884.
41. Marcinek DJ, Schenkman KA, Ciesielski WA, Lee
D, Conley KE. Reduced mitochondrial coupling in
vivo alters cellular energetics in aged mouse skeletal muscle. J Physiol. 2005;569(pt 2):467–473.
42. Navarro A, Boveris A. The mitochondrial energy
transduction system and the aging process. Am J

Physiol Cell Physiol. 2007;292(2):C670–C686.
43. Ryan LM, Rachow JW, McCarty DJ. Synovial
fluid ATP: a potential substrate for the production of inorganic pyrophosphate. J Rheumatol.
1991;18(5):716–720.
44. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer
JL, Harden TK. Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol. 2003;64(5):1210–1216.
45. Dorsam RT, Kunapuli SP. Central role of the
P2Y12 receptor in platelet activation. J Clin Invest.
2004;113(3):340–345.
46. Kronlage M, et al. Autocrine purinergic receptor
signaling is essential for macrophage chemotaxis.
Sci Signal. 2010;3(132):ra55.
47. McHugh KP, et al. Mice lacking beta3 integrins are
osteosclerotic because of dysfunctional osteoclasts.
J Clin Invest. 2000;105(4):433–440.
48. Falker K, Lange D, Presek P. P2Y12 ADP receptordependent tyrosine phosphorylation of proteins
of 27 and 31 kDa in thrombin-stimulated human
platelets. Thromb Haemost. 2005;93(5):880–888.
49. Kauffenstein G, et al. The P2Y(12) receptor induces
platelet aggregation through weak activation of
the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett.
2001;505(2):281–290.
50. Gao L, et al. Ras-associated protein-1 regulates
extracellular signal-regulated kinase activation and
migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis.
Cancer Res. 2006;66(16):7880–7888.
51. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin
Invest. 2003;111(5):749–758.
52. Bradley EW, Ruan MM, Vrable A, Oursler MJ.
Pathway crosstalk between Ras/Raf and PI3K
in promotion of M-CSF-induced MEK/ERKmediated osteoclast survival. J Cell Biochem. 2008;
104(4):1439–1451.
53. Korganow AS, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via
immunoglobulins. Immunity. 1999;10(4):451–461.
54. Savi P, et al. The active metabolite of Clopidogrel
disrupts P2Y12 receptor oligomers and partitions
them out of lipid rafts. Proc Natl Acad Sci U S A.
2006;103(29):11069–11074.
55. Smyth SS, Tsakiris DA, Scudder LE, Coller BS.
Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): studies using monoclonal
antibodies and beta3-null mice. Thromb Haemost.
2000;84(6):1103–1108.
56. Novack DV, Teitelbaum SL. The osteoclast: friend
or foe? Annu Rev Pathol. 2008;3:457–484.
57. De Simone R, Niturad CE, De Nuccio C, AjmoneCat MA, Visentin S, Minghetti L. TGF-beta and
LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression. J Neurochem. 2010;115(2):450–459.
58. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC. Rap1b is
required for normal platelet function and hemostasis in mice. J Clin Invest. 2005;115(3):680–687.
59. Chrzanowska-Wodnicka M, Kraus AE, Gale D,
White GC, Vansluys J. Defective angiogenesis,
endothelial migration, proliferation, and MAPK
signaling in Rap1b-deficient mice. Blood. 2008;
111(5):2647–2656.
60. Dorsam RT, Kim S, Jin J, Kunapuli SP. Coordinated
signaling through both G12/13 and G(i) pathways
is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem. 2002;277(49):47588–47595.
61. Irino Y, Nakamura Y, Inoue K, Kohsaka S, Ohsawa
K. Akt activation is involved in P2Y12 receptormediated chemotaxis of microglia. J Neurosci Res.
2008;86(7):1511–1519.
62. Jantzen HM, Milstone DS, Gousset L, Con-

The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012

3591

Downloaded on October 17, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/38576

research article
ley PB, Mortensen RM. Impaired activation of
murine platelets lacking G alpha(i2). J Clin Invest.
2001;108(3):477–483.
63. Itzstein C, Coxon FP, Rogers MJ. The regulation of
osteoclast function and bone resorption by small
GTPases. Small GTPases. 2011;2(3):117–130.
64. Ito Y, et al. Cdc42 regulates bone modeling and
remodeling in mice by modulating RANKL/M-CSF
signaling and osteoclast polarization. J Clin Invest.
2010;120(6):1981–1993.
65. Iyu D, et al. Mode of action of P2Y(12 ) antagonists
as inhibitors of platelet function. Thromb Haemost.
2011;105(1):96–106.
66. Jackson SW, et al. Disordered purinergic signaling
inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol. 2007;171(4):1395–1404.
67. Uluckan O, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in
mice. J Cell Biochem. 2008;104(4):1311–1323.
68. Winning J, Claus RA, Pletz MW, Bauer M, Losche
W. Adenosine diphosphate receptor antagonist
clopidogrel sulfate attenuates LPS-induced sys-

3592

temic inflammation in a rat model. Shock. 2011;
36(3):317–318.
69. Reynolds LE, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and
beta5 integrins. Nat Med. 2002;8(1):27–34.
70. Robinson SD, Hodivala-Dilke KM. The role of
beta3-integrins in tumor angiogenesis: context is
everything. Curr Opin Cell Biol. 2011;23(5):630–637.
71. Suva LJ, et al. Platelet dysfunction and a high
bone mass phenotype in a murine model of
platelet-type von Willebrand disease. Am J Pathol.
2008;172(2):430–439.
72. Morgan EA, et al. Dissection of platelet and myeloid
cell defects by conditional targeting of the beta3integrin subunit. FASEB J. 2010;24(4):1117–1127.
73. Vestergaard P, Steinberg TH, Schwarz P, Jørgensen
NR. Use of the oral platelet inhibitors dipyrida
mole and acetylsalicylic acid is associated with
increased risk of fracture [published online ahead
of print April 2, 2011]. Int J Cardiol. doi:10.1016/
j.ijcard.2011.03.026.
74. Michelson AD. New P2Y12 antagonists. Curr Opin

Hematol. 2009;16(5):371–377.
75. Hodivala-Dilke KM, et al. Beta3-integrin-deficient
mice are a model for Glanzmann thrombasthenia
showing placental defects and reduced survival.
J Clin Invest. 1999;103(2):229–238.
76. Léon C, et al. Defective platelet aggregation
and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest.
1999;104(12):1731–1737.
77. Uluckan O, et al. CD47 regulates bone mass
and tumor metastasis to bone. Cancer Res. 2009;
69(7):3196–3204.
78. Smith MC, et al. CXCR4 regulates growth of both
primary and metastatic breast cancer. Cancer Res.
2004;64(23):8604–8612.
79. Gross S, Piwnica-Worms D. Real-time imaging of
ligand-induced IKK activation in intact cells and
in living mice. Nat Methods. 2005;2(8):607–614.
80. Lai CF, et al. Accentuated ovariectomy-induced
bone loss and altered osteogenesis in heterozygous
N-cadherin null mice. J Bone Miner Res. 2006;
21(12):1897–1906.

The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012

